Objective. Academic detailing (AD) is a promising intervention to address the growing morbidity and mortality associated with opioids. While AD has been shown to be effective in improving provider prescribing practices across a range of conditions, it is unclear how best to implement AD. The present study was designed to identify key lessons for implementation based on a model AD program in the Veterans Health Administration (VA). Design. Qualitative process evaluation using semistructured interviews. Setting. Seven VA health care systems in the Sierra Pacific region. Subjects. Current and former academic detailers (N ¼ 10) and VA providers with varying exposure to AD (high, low, or no; N ¼ 20). Methods. Semistructured interviews were audio-recorded and transcribed. We used a teambased, mixed inductive and deductive approach guided by the Consolidated Framework for Implementation Research. Results. Key lessons identified by academic detailers and providers coalesced around key themes: 1) one-onone sessions customized to the provider's patient population are most useful; 2) leadership plays a critical role in supporting providers' participation in AD programs; 3) tracking academic detailer and provider performance is important for improving performance for both groups; 4) academic detailers play a key role in motivating provider behavior change and thus training in Motivational Interviewing is highly valuable; and 5) academic detailers noted that networking is important for sharing implementation strategies and resources. Conclusions. Identifying and incorporating these key lessons into the implementation of complex interventions like AD are critical to facilitating uptake of evidencebased interventions addressing the opioid epidemic.
Introduction
Academic detailing (AD) is an effective educational outreach strategy that relies on experts, known as academic detailers (herein referred to as "detailers"), to engage frontline clinicians in communication to improve prescribing practices and clinical decision-making. The model for AD was initially proposed and tested in the early 1980s to alter suboptimal prescribing behavior through evidence-based education delivered face to face, predominantly by clinical pharmacists [1] . Since that time, multiple studies have demonstrated its effectiveness as a sole intervention or as part of a multicomponent intervention to improve providers' prescribing behavior [2] .
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Hallmarks of AD are in-person outreach, use of evidence-based information and resources, reliance on health care professionals trained in empathic persuasive communication, and development of a trusted relationship between detailer and provider. Academic detailing is distinguished from other education efforts in that the intervention is intended to encourage and promote voluntary action rather than enforce behavior change. Needs assessment, delivery of key messages, identification of benefits to behavior change, and barrier resolution all contribute to a successful AD interaction [3, 4] .
It is increasingly urgent to explore effective interventions such as AD to address morbidity and mortality associated with opioids. From 2000 to 2014, the number of opioid overdoses has tripled, with increases in overdose deaths being driven largely by prescription opioid pain relievers and more recently by illicit heroin. Of further concern is that drug overdose deaths involving synthetic opioids nearly doubled between 2013 and 2014 [5] . While AD is not intended to address illicit drug use directly, past misuse of prescription opioids is a strong risk factor for illicit drug use, such as heroin [6] .
A comprehensive approach, including AD, is needed to address the opioid epidemic. Detailers work with providers to taper patients on risky opioid regimens and promote nonpharmacological treatments for pain management. They also work with providers to increase use of medication-assisted therapy for opioid abuse [7] and provide additional information about opioid overdose reversal [8] .
Although original trials examining the effectiveness of AD did not focus on addressing opioids, there has been increasing interest in the use of AD to address widespread unsafe opioid prescribing practices, misuse, and abuse [9, 10] . Recent research has demonstrated its effectiveness in this context [11] [12] [13] .
The Veterans Health Administration (VA) is a leader in applying AD to address the opioid epidemic. In March 2015, the VA's Interim Under Secretary for Health issued a memo calling for system-wide implementation of AD programs, delivered by trained clinical pharmacists. The memo outlined key focus areas of the to-be-implemented AD programs, including practices to reduce morbidity and mortality associated with opioids. Additionally, the memo cited data from seven early-adopting health care systems (including 50 associated clinics) in the Sierra Pacific region that demonstrated a positive impact on key metrics related to opioid safety [14] . Because these facilities have used AD since 2010, they served as an ideal laboratory for identifying key lessons to inform and facilitate implementation of similar AD interventions focused on opioid safety.
We partnered with the Sierra Pacific region's AD program leaders to conduct a qualitative process evaluation of implementation of AD from the perspective of detailers and providers. We hypothesized that detailers could provide us with the most in-depth lessons to inform implementation because they were primarily responsible for implementing and delivering AD. We selected providers with a range of exposure to AD in order to compare and contrast their perceptions of AD, as exposure to the intervention can impact perceptions [15] . We hypothesized that providers with low and high levels of exposure to AD could provide feedback on what contributed to successes or failures of AD implementation, while providers with no exposure could provide insight into resistance to AD and better ways to engage reluctant providers.
Methods

Interview Guide Development
Interview guide development was informed by the Consolidated Framework for Implementation Research (CFIR), a meta-theoretical framework that includes five domains and 39 constructs relevant to implementation evaluation [16] . Using CFIR as a guide, we developed interview guides for detailers and providers. We chose constructs from four of the five CFIR domains-intervention characteristics, inner setting, process, and characteristics of individuals. Our team then worked with AD program leaders to iteratively revise the guides. AD program leaders included the pharmacy executive, the pharmacy program manager, and two regional data pharmacists for the Sierra Pacific region. We also conducted pilot interviews with two detailers and two providers and incorporated that feedback.
Participant Recruitment
We recruited current and former detailers and providers from within the Sierra Pacific region. Data provided by the AD program leaders were used to stratify providers according to their level of exposure; providers were then randomized for recruitment. High-exposure providers had one or more AD sessions, lasting 50 or more minutes, in which opioid safety was discussed for at least half of the visit. Low-exposure providers had one or more AD sessions, lasting fewer than 50 minutes, in which opioid safety was discussed. Nonexposed providers had large numbers of patients on high-dose opioids and had been contacted by a detailer, but did not respond or declined. Nonexposed providers were identified using a combination of snowball (detailer recommendations) and purposeful sampling of providers.
Data Collection and Analysis
Semistructured telephone (N ¼ 23) and in-person (N ¼ 7) interviews were conducted between February and May 2016. Interviews were audio-recorded and transcribed. Because the CFIR is complex (with five domains and 39 constructs) and because we anticipated that some constructs would be more relevant to implementation than others, we conducted a mixed inductive and deductive, two-step analytic process.
For the first step, questions from the CFIR-informed interview guides were used to develop a structured template for summarizing verbatim transcripts that included identification of illustrative quotes. Summary template development involved independent coding of a single transcript by the qualitative lead (RCG) and analysts (JW, TE), followed by a consensus meeting to refine the template. This process was repeated prior to finalizing the template and dividing transcripts among the analytic team. After all interviews were summarized, the qualitative lead (RCG) reviewed a subset of the summaries to ensure consistency across the team. Summaries were subsequently consolidated into a series of Excel matrices based on participant type to facilitate display of the data [17] . These matrices were used to identify commonly identified categories of lessons learned.
For the second step, the commonly identified categories of lessons learned were used to develop and refine a CFIR-based codebook (i.e., what CFIR construct/domain the commonly identified lessons fell into). The initial codebook was refined after two successive consensus coding exercises, prior to coding all transcripts using ATLAS.ti (version 7). Each transcript was coded in duplicate by two members of the evaluation team (RCG, JW, TE, MB), and discrepancies were resolved by consensus.
Ensuring trustworthiness, defined as credibility, transferability, dependability, and confirmability, is important when conducting rigorous qualitative studies [18] . To address these indicators of trustworthiness, we developed a structured interview guide that was informed by an established implementation framework (CFIR). The interview guide itself was pilot tested and revised prior to the interviews. The interview team was comprised of multiple members, and more than one team member joined most interviews. Notes were taken during interviews, and participants were asked to clarify or elaborate on unclear responses to ensure that the team accurately captured experiences. Team members were debriefed after each interview. To ensure transferability of findings, participant characteristics and the evaluation setting were well documented. This project met the definition of quality improvement and was determined by the Stanford University Institutional Review Board as nonhuman subjects research.
Results
The evaluation team interviewed 10 current (N ¼ 7) and former (N ¼ 3) detailers and 20 providers in the Sierra Pacific region. In the detailer group, 100% of eligible detailers agreed to an interview. In the high-exposure provider group, six out of 17 (35%) eligible providers agreed to an interview. In the low-exposure provider group, seven out of 31 (26%) eligible providers agreed. In the nonexposed group, seven out of 84 (8%) eligible providers agreed. The sample sizes for both detailers and providers are in line with estimates in the literature for achieving thematic saturation when using purposive sampling techniques [19] .
Detailers were all clinical pharmacists. Detailer interviews ranged in length from 37 to 60 minutes. Provider interviews ranged from nine to 33 minutes, with interviews with nonexposed providers being the shortest. Sixteen of the 20 providers (80%) interviewed worked in primary care. Providers included 15 physicians (six of whom were physician leaders), three advance practice nurses, and two psychologists (one of whom was a mental health leader). Additional participant characteristics are provided in Table 1 .
Detailers and providers identified several key features of effective AD programs related to opioid safety, as well as ways to facilitate behavior change in providers. Although we hypothesized that provider perspectives would differ based on their level of exposure to AD, themes were mostly consistent across groups, ultimately resulting in the decision to collapse findings from the provider groups into a single cohort. However, themes endorsed predominantly by a single provider group are noted.
Key features identified by detailers fell into five categories: 1) provider engagement and interactions; 2) detailer training; 3) leadership support; 4) performance 
Detailer Perspective
Provider Engagement and Interactions Most detailers (N ¼ 7, 70%) described the importance of allocating sufficient time to prepare for provider visits, including conducting individual needs assessments to tailor sessions to individual providers' needs and those of their patient population. One detailer quantified the allocation of detailing activities: "I would say that I probably spent 25% of my time actually face to face, and the other 75% of that time was spent on the background processes or the development and making sure I had all my ducks in a row before I met with providers." All detailers (N ¼ 10) noted the value of using informatics dashboards to identify target providers and patients as well as teaching providers to use these tools to monitor their patient panels: "I use the dashboard to look at physicians who are outliers in prescribing. . . . I educate providers and staff on how to use the dashboard so they can find their patients. . . . It's a really dashboarddriven process."
Most detailers (N ¼ 9, 90%) noted the importance of conducting visits one on one and face to face whenever possible. "I think most effective are my face-to-face visits. . . . I feel like I'm more able to engage with them. . .because that's when they're more able to express what their struggles are."
Additionally, a majority of detailers (N ¼ 9, 90%) emphasized the importance of persistence and flexibility in outreach to providers, given providers' hectic schedules and other barriers. One detailer noted, "I didn't feel bad about sending multiple emails. . . . I have IMed providers, I have cold-called providers. . . . You know, I get the clinic manager to buy in, do a small presentation and say, 'I'll be sitting in the lobby with my laptop, please come get me if you have any additional questions,' so I've had 'em come approach me that way. I've had pharmacists introduce me to their additional team members so that I could get in that way. So just multiple routes."
Detailer Training
All detailers stated that in-person training was highly valuable, in part to meet and share best practices among detailers but also to acquire more skills and knowledge. One detailer noted, "I'm a big proponent of face-to-face meetings. . .bringing in experts to give presentations on [detailing topics] to make sure that you have the appropriate background on it, bringing in physician champions so that you can actually practice the modules on them, make sure that the key messages that you're talking about are going to be well accepted." Most detailers (N ¼ 8, 80%) reported that they highly valued training in Motivational Interviewing, with some of them expressing the desire for more training opportunities. One detailer noted, "You have a lot of hesitant providers, but you have to use the Motivational Interviewing skills to get them to see where we're coming from."
Leadership Support
All detailers described leadership buy-in and support as essential to being able to promote AD and engage providers. A detailer noted, "I had to start having some things sent out from the Chief of Staff office. Performance Tracking While much of detailers' time is spent tracking provider performance on target metrics, most detailers (N ¼ 9, 90%) noted monitoring their own performance in three main ways. First, some noted using an informatics dashboard to review the performance of providers they met with to track improvements of the metrics targeted during detailing meetings. Second, detailers mentioned periodically reviewing data entered in a tracking database to monitor the number of providers they have detailed, the number of encounters, and the breakdown of the content covered during each of those sessions into a tracking database. Third, they review results from provider satisfaction surveys to assess and alter their performance accordingly.
Strong Networks
Detailers identified two main ways to leverage networks-engaging with or becoming a member of local pain committees to increase visibility and clout (N ¼ 9, 90%) and networking with fellow detailers to share best practices and resources. One detailer noted, "I would take things or share things with the pain committee. . . . The pain committee was actually very helpful to. . .push things up to higher leadership." All detailers endorsed the importance of regular interaction with fellow detailers and noted several ways they network-online (e.g., SharePoint, internal VA social network website), conference calls, and in-person meetings-which are coordinated by either regional or national AD leadership.
Provider Perspective
Detailer Engagement and Interactions with Providers
In addition to spurring already motivated providers into action and helping to track their progress, most providers (N ¼ 15, 75%) spoke of the importance of receiving messages that are tailored and relevant to the patient population they care for. A high-exposure provider noted, "What [our detailer] has developed I think is definitely an improvement after all the years that I've been with the VA. The reason is because, again, [the program is] very focused, very patient-driven, meaning we are actually working with our panel of patients with very specific things to work on."
Like detailers, over half of providers (N ¼ 11, 55%) noted the importance of having one-on-one detailing sessions. A low-exposure provider stated, "I think an obvious first strength is one-on-one interaction as opposed to sitting in a group setting or doing something online. The dialogue can be tailored to the interest and to the level of understanding. So, that makes a big difference."
Ability to Motivate Behavior Change Primarily exposed providers (N ¼ 8, 62%) spoke of the value of AD to motivate change, with only one unexposed provider noting that benefit. One high-exposure provider said, "I was motivated to take action before I met the detailer, but she was-she probably was a nice catalyst to help it come to fruition, help my motivation, enhance my motivation to bring. . .forth a performance."
Perceived Value of Detailing
Most providers (N ¼ 12, 60%) appreciated having a service that would allow them to receive evidence-based assistance from qualified peers. One high-exposure provider noted, "It felt valuable to us because now we've got somebody who can talk from the evidence-based perspective about what different options are available to our primary care providers, which is something we've been trying to do for years." At the same time, half of the providers (N ¼ 10) noted that leadership and peers did not necessarily know about the program, and it was important to educate others about AD benefits.
Materials and Resources
Most of the exposed providers (N ¼ 12, 92%) commented on the value of receiving educational materials from detailers during meetings, with only two unexposed providers noting this benefit. While provider needs can vary, there was consensus across groups that they appreciated reference guides (e.g., opioid conversion table, urine drug screen interpretation), patient pamphlets, and websites with critical information.
Performance Tracking
Most of the exposed providers (N ¼ 11, 85%) discussed the value of performance tracking for monitoring progress over time, with only two unexposed providers noting this benefit. One high-exposure provider, who was also part of clinical leadership, said having an informatics dashboard that tracked providers' prescribing patterns helped prioritize providers for AD intervention: "We had three prescribers prescribing something like 15% of our opiates. . . . So, at the leadership level, once I began to understand the variation that was occurring, it helped me to then formulate some approaches."
Leadership Support
Providers across all groups emphasized the important role of leadership (N ¼ 12, 60%). They noted that leaders within their network were supportive of participation in AD for opioid safety, but multiple providers (N ¼ 8, 40%) specifically expressed a desire for leadershipsanctioned, protected time to participate in the AD program. One unexposed provider stated, "A lot of times when they have programs, they don't bother canceling our patients, so in the middle of us trying to take care of the veterans they'll have a program that I can't go to."
Discussion
This qualitative process evaluation of a long-standing, effective, model AD program revealed several key lessons for implementation of AD programs focused on prevention and treatment of opioid-associated morbidity and mortality. Provider and detailer responses coalesced around several themes: 1) one-on-one sessions customized to providers' patient populations are the most useful; 2) leadership plays a critical role in endorsing and supporting providers to participate in AD programs; 3) tracking detailer as well as provider performance is important to improve performance in both groups; 4) detailers are important in motivating provider change, and detailer training in Motivational Interviewing is useful; and 5) networking among detailers is invaluable for sharing implementation strategies and resources.
There was clear consensus among detailers and providers that one-on-one, in-person meetings were preferred over group sessions. While there is evidence that group-administered AD is equivalent in effectiveness to individually administered AD [20, 21] , there is also evidence that individually administered AD is more effective [22] . However, none of these trials targeted changing provider behavior related to opioid prescribing for chronic pain or treating addiction related to opioids. Primary care providers have consistently reported feeling a lack of confidence in managing their chronic pain patients, including those receiving opioids [23, 24] . Similarly, they have also reported uncertainty in providing overdose education and naloxone [25, 26] and treating patients with opioid addiction [27] . In the case of AD related to opioid safety, it may be particularly important to prioritize one-on-one, in-person interactions so that unique challenges perceived by providers can be addressed by the detailer. As consistently noted by detailers and providers, AD's value lies not solely in education but in barrier resolution and tailoring the detailing session to the needs of the provider. One particular need for providers may be addressing their lack of confidence and concerns related to opioid prescribing and opioid addiction through the use of Motivational Interviewing.
While motivating providers was a feature of the original AD program [1] , there has been a relatively recent effort to integrate Motivational Interviewing into the AD model to accomplish this goal. This therapeutic approach was originally developed for use to treat individuals with problem drinking [28] , but it has been shown to be effective in facilitating behavior change in a wide range of populations [29] . There is limited evidence for its effectiveness when it is delivered solely in a group format as opposed to individual [30] , further speaking to the importance of individually administered AD for changing providers' behavior related to opioid safety.
The original models of AD include involvement of key opinion leaders in promulgating AD [31] . The current evaluation's findings provide additional, more explicit suggestions for ways to engage leadership to enhance support for AD related to opioid safety. Specifically, detailers should take time to engage with clinical and organizational leadership (e.g., chief of staff, pain committees) at their health care facility to facilitate provider participation in AD, through mandating change or more "top-down" influence from clinical leadership [32] . Given the number of priorities leadership is likely juggling, it is important to highlight the evidence for the value of the AD program, providing data that supports its effectiveness in meeting key metrics and noting provider and patient support of AD whenever possible.
Both providers and detailers emphasized the importance of performance tracking, a hallmark of good quality improvement programs [33] . This finding is also in line with research showing the effectiveness of audit and feedback in altering the behavior of health care professionals, particularly when feedback is delivered with greater frequency and with specific targets [34] . One advantage of the AD program evaluated in this study is that participants leverage administrative data displayed in an informatics dashboard to monitor provider progress over time. Detailers can modify interventions with key providers based on changes in provider performance on specific metrics, and providers can self-monitor and specifically target areas where they need to improve (e.g., increased naloxone prescribing).
One final theme that emerged was the value of building networks locally and nationally. By building relationships with local pain specialists and committee members at their facility, detailers could increase the visibility of and facilitate AD implementation. They also noted the importance of building peer networks of other detailers with whom they could share materials and resources, something highly valued by providers. Building peer networks and communities of practice can be a valuable implementation strategy [32, 35] and should be a priority for those implementing AD programs.
Although this evaluation provided unique insight into key lessons from a long-standing AD program, there are limitations. Data collection was limited to a single VA region. It is possible that features of effective AD were unique to this setting; however, we attempted to minimize this possibility by including participants from each of the seven disparate medical facilities within the region as well as all current and former detailers. While the sample was limited to 10 participants, the number is in line with sampling frame estimates to achieve thematic saturation when using purposive sampling [19] . Participant self-selection bias is a potential threat to the generalizability of the findings from providers. Although a multimodal approach to provider recruitment was used, most providers (85%, N ¼ 112) refused to be interviewed, particularly those with limited or no exposure to the AD program. This sampling bias could indicate that providers with more favorable attitudes about the program might have been more likely to share their opinions. However, it is noteworthy that a range of both positive and negative thoughts from participants were identified.
Conclusions
These findings have implications for the national implementation of AD programs across the VA, mandated by Interim Under Secretary for Health in 2015, but they are also highly relevant to policy and clinical leadership across non-VA health care facilities attempting to build and implement AD programs to address the growing morbidity and mortality from use and abuse of opioids.
The VA has systemic advantages over the private sector, such as robust data information systems for health informatics applications, as well as centralized sponsorship and messaging surrounding AD. However, the VA's experiences around best practices for AD implementation incorporate not only systemically focused findings, but also data that concentrate on the interpersonal interactions between detailers and providers. This knowledge can be applied to a variety of health care entities, particularly those that are similarly large-scale and integrated.
Furthermore, the VA's Academic Detailing program has pursued partnerships with other national leaders in AD, including the National Resource Center for Academic Detailing (NaRCAD). These partnerships can be leveraged to promote mutual learning and used to facilitate the spread of AD both within the VA and outside of it.
